NeuroBioPharm Reports Results of Annual General Meeting
2014年6月20日 - 10:46PM
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation") a Neptune
Technologies & Bioressources Inc. subsidiary ("Neptune")
(Nasdaq:NEPT) (TSX:NTB) announces that at its Annual General
Meeting (the "Meeting"), held on June 19, 2014, the Corporation's
shareholders voted in favour of all items put forth at the Meeting
and outlined in the Corporation's management proxy circular dated
May 22, 2014 (the "Circular") available on SEDAR at www.sedar.com
and EDGAR at www.sec.gov/edgar.shtml.
Changes to the Board of Directors
Shareholders re-elected Dr. Ronald Denis and Valier Boivin. As
well, five new directors were elected, including, Mr. Pierre
Fitzgibbon, Mr. Adrian Montgomery, Dr. Reed V. Tuckson, Dr. Harlan
W. Waksal and Mr. Jerald J. Wenker.
"On behalf of NeuroBioPharm's Board of Directors and management
team, I would like to welcome our new Board members," commented Mr.
André Godin, Interim President and Chief Executive Officer.
"NeuroBioPharm's shareholders have elected a strong slate of
directors who bring deep industry experience in health, nutrition,
finance, sales and marketing and have a solid track record of value
creation in their respective areas. We will benefit from their
leadership and experience as we move forward with our growth
initiatives."
As previously announced, Mr. Henri Harland, Mr. Jean-Claude
Debard and Mr. Daniel Perry did not stand for re-election to the
Board. Mr. Perry resigned from the Board on June 18, 2014.
About NeuroBioPharm Inc.
NeuroBioPharm ("NeuroBio") is an emerging biopharmaceutical
company focused on the research, development and commercialization
of new marine based omega-3 phospholipid therapies for use in the
human neurological field, including conditions, abnormalities
and/or diseases related to cognitive functions such as attention,
memory, concentration and learning and the management of
neurological and neurodevelopmental disorders from prevention to
treatment. The Corporation is currently in the early stages of
developing novel active pharmaceutical ingredients ("API") into
commercial products for the medical food, the over-the-counter
("OTC") and the prescription drug markets. Particular focus is
being given to ADHD; cognitive functions, including memory and
concentration; along with mood disorders, such as anxiety and
depression.
About Neptune Technologies & Bioressources
Inc.
Neptune is a biotechnology company engaged primarily in the
development and commercialization of marine-derived omega-3
polyunsaturated fatty acids (''PUFAs''). Neptune has a patented
process of extracting oils from Antarctic krill, and principally
sells omega-3 PUFAs as bulk oil to Neptune's distributors who
commercialize them under their private label primarily in the U.S.,
European and Australian nutraceutical markets. Neptune's products
generally come in bulk oil or capsule form and serve as a dietary
supplement to consumers. Neptune's head office is located at 545
Promenade du Centropolis, Suite 100, Laval, Quebec.
Neptune respectively holds approximately 49% of the
participating and voting rights of Acasti and 95% of the voting
rights of NeuroBioPharm. Through these subsidiaries, Neptune is
also pursuing opportunities in the medical food and prescription
drug markets. Acasti and NeuroBioPharm respectively focus on the
research and development of safe and therapeutically effective
compounds for highly prevalent atherosclerotic conditions, such as
cardiometabolic disorders and cardiovascular diseases, and for
neurodegenerative and inflammation related conditions. Acasti's
lead prescription drug candidate is CaPre®, a purified high omega-3
phospholipid concentrate derived from Neptune krill oil being
developed to address the prevention and treatment of
cardiometabolic disorders, including hypertriglyceridemia, which is
characterized by abnormally high levels of triglycerides.
Forward Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. securities laws and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Neptune to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in
Neptune and NeuroBio's public securities filings with the
Securities and Exchange Commission and the Canadian securities
commissions. Except as required by law, Neptune and NeuroBio
disclaim any intention or obligation to update or revise any
forward-looking statements.
"Neither NASDAQ nor the Toronto Stock Exchange accepts
responsibility for the adequacy or accuracy of this release."
CONTACT: Neptune Contacts:
Andre Godin
Chief Financial Officer
+1.450.687.2262
a.godin@neptunebiotech.com
neptunebiotech.com
John Ripplinger
Investor Relations
+1.450.687.2262
j.ripplinger@neptunebiotech.com
neptunebiotech.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 9 2024 まで 10 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 10 2023 まで 10 2024